This study investigates gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
The study evaluates the safety and effectiveness of an investigational treatment compared to standard care for patients with GEP-NETs.
- Who can participate: Adults with advanced, inoperable GEP-NETs that are SSTR-PET positive and have progressed after specific prior treatments can participate. Adequate kidney and blood function are required.
- Study details: Participants will receive either the investigational medication or standard care. Some may receive a placebo, an inactive substance that looks like the investigational medicine but does not contain any medicine.